文章：

靶向癌症中的c-MET基因改变：遗传驱动因素与治疗意义综述

Targeting c-MET Alterations in Cancer: A Review of Genetic Drivers and Therapeutic Implications

原文发布日期：29 April 2025

DOI: 10.3390/cancers17091493

类型: Article

开放获取: 是

英文摘要：

Background: Recent research has increasingly highlighted alterations in the proto-oncogeneMET, whose abnormal activation has been implicated in multiple cancers.METencodes c-MET, a receptor tyrosine kinase critical for cellular growth, survival, and migration. Aberrant c-MET signaling, driven by mutations or gene amplification, promotes proliferation and invasion, contributing to tumorigenesis. Scope of the Review: WhileMETmutations are most often observed in non-small cell lung cancer (NSCLC), they also occur in other malignancies, including breast and gastric cancers. This review highlights keyMETalterations, such as gene amplification, gene fusions, and exon 14 skipping deletions, and examines their prevalence across various tumor types. Major Conclusions: We discuss the clinical significance of c-MET as a therapeutic target and identify gaps in knowledge that could inform the development of alternative treatment strategies.

摘要翻译： 

背景：近期研究日益凸显原癌基因MET的变异，其异常激活与多种癌症相关。MET编码c-MET受体酪氨酸激酶，该蛋白对细胞生长、存活及迁移至关重要。由基因突变或扩增驱动的c-MET信号通路异常会促进细胞增殖与侵袭，从而参与肿瘤发生。综述范围：尽管MET突变最常见于非小细胞肺癌，但在乳腺癌、胃癌等其他恶性肿瘤中亦有发现。本综述重点探讨MET基因扩增、基因融合及外显子14跳跃缺失等关键变异类型，并分析其在不同肿瘤类型中的分布特征。核心结论：我们系统阐述c-MET作为治疗靶点的临床意义，同时指出当前认知空白，为开发新型治疗策略提供方向。

原文链接：

Targeting c-MET Alterations in Cancer: A Review of Genetic Drivers and Therapeutic Implications